Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, et al.
iScience (2020) Vol. 24, Iss. 1, pp. 101992-101992
Open Access | Times Cited: 79

Showing 26-50 of 79 citing articles:

Recent advances in small-molecular therapeutics for COVID-19
Lei Zhong, Zhipeng Zhao, Xuerun Peng, et al.
Precision Clinical Medicine (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 21
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Lina Kamal, Ahmed Ramadan, Suha A. Farraj, et al.
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 5, pp. 508-518
Open Access | Times Cited: 20
In Silico Study of Entry Inhibitor from Moringa oleifera Bioactive Compounds against SARS-CoV-2 Infection
Nala Mawaddani, Ekris Sutiyanti, Muhammad Hermawan Widyananda, et al.
Pharmacognosy Journal (2022) Vol. 14, Iss. 5, pp. 565-574
Open Access | Times Cited: 18
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2
Kiran Shehzadi, Afsheen Saba, Mingjia Yu, et al.
Topics in Current Chemistry (2023) Vol. 381, Iss. 5
Closed Access | Times Cited: 11
Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytocompounds against SARS-CoV-2 proteins
Chinmayi Joshi, Armi Chaudhari, Chaitanya G. Joshi, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 18, pp. 8405-8419
Open Access | Times Cited: 26
Interface‐based design of the favipiravir‐binding site in SARS‐CoV‐2 RNA‐dependent RNA polymerase reveals mutations conferring resistance to chain termination
Aditya K. Padhi, Jagneshwar Dandapat, Prakash Saudagar, et al.
FEBS Letters (2021) Vol. 595, Iss. 18, pp. 2366-2382
Open Access | Times Cited: 26
Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation
Aditya K. Padhi, Timir Tripathi
Biochemical and Biophysical Research Communications (2021) Vol. 555, pp. 147-153
Open Access | Times Cited: 25
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor
Sajjan Rajpoot, Tomokazu Ohishi, Ashutosh Kumar, et al.
Drugs in R&D (2021) Vol. 21, Iss. 3, pp. 273-283
Open Access | Times Cited: 25
An integrated understanding of the evolutionary and structural features of the SARS-CoV-2 spike receptor binding domain (RBD)
Dwipanjan Sanyal, Suharto Banerjee, Aritra Bej, et al.
International Journal of Biological Macromolecules (2022) Vol. 217, pp. 492-505
Open Access | Times Cited: 17
Role of artificial intelligence in peptide vaccine design against RNA viruses
Eileena Mohanty, Anima Mohanty
Informatics in Medicine Unlocked (2021) Vol. 26, pp. 100768-100768
Open Access | Times Cited: 22
Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches
Saad Al Zamane, Fahim Alam Nobel, Ruksana Akter Jebin, et al.
Informatics in Medicine Unlocked (2021) Vol. 27, pp. 100781-100781
Open Access | Times Cited: 20
Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function
Sk. Sarif Hassan, Kenneth Lundström, Ángel Serrano‐Aroca, et al.
International Journal of Biological Macromolecules (2021) Vol. 194, pp. 128-143
Open Access | Times Cited: 20
Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets
Tao Yang, Si Chun Wang, Linyan Ye, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 247-268
Closed Access | Times Cited: 8
Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2
José Xavier Neto, Katyanna Sales Bezerra, Emmanuel Duarte Barbosa, et al.
Frontiers in Molecular Biosciences (2024) Vol. 10
Open Access | Times Cited: 2
In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2
Agnieszka M. Szemiel, Andres Merits, Richard Orton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences
Suzana Corritori, Nikolay P. Savchuk, C. David Pauza
COVID (2022) Vol. 2, Iss. 8, pp. 1057-1076
Open Access | Times Cited: 12
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
Evelyn J. Franco, George L. Drusano, Kaley C. Hanrahan, et al.
Viruses (2023) Vol. 15, Iss. 5, pp. 1175-1175
Open Access | Times Cited: 7
Drug-Based Therapeutic Strategies for COVID-19-Infected Patients and Their Challenges
Khatereh Zarkesh, Elaheh Entezar-Almahdi, Parisa Ghasemiyeh, et al.
Future Microbiology (2021) Vol. 16, Iss. 18, pp. 1415-1451
Open Access | Times Cited: 16
African derived phytocompounds may interfere with SARS-CoV-2 RNA capping machinery via inhibition of 2′-O-ribose methyltransferase: An in silico perspective
Gideon Ampoma Gyebi, Oludare M. Ogunyemi, Adedotun A. Adefolalu, et al.
Journal of Molecular Structure (2022) Vol. 1262, pp. 133019-133019
Open Access | Times Cited: 11
Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir
Supasek Kongsomros, Ampa Suksatu, Phongthon Kanjanasirirat, et al.
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1230-1230
Open Access | Times Cited: 14
Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2
Meng Wang, Huimin Yan, Lü Chen, et al.
PLoS ONE (2023) Vol. 18, Iss. 5, pp. e0285722-e0285722
Open Access | Times Cited: 5
From De Novo Design to Redesign: Harnessing Computational Protein Design for Understanding SARS-CoV-2 Molecular Mechanisms and Developing Therapeutics
Aditya K. Padhi, Parismita Kalita, Shweata Maurya, et al.
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 41, pp. 8717-8735
Closed Access | Times Cited: 5
Theoretical Description for Anti-COVID-19 Drug Molnupiravir Electrochemical Determination over the Poly-((1,2,4-triazole)-co-(squaraine dye)) Composite with Cobalt (III) Oxyhydroxide
Volodymyr Tkach, Marta V. Kushnir, Sílvio De Oliveira, et al.
Biointerface Research in Applied Chemistry (2022) Vol. 13, Iss. 1, pp. 74-74
Open Access | Times Cited: 9
A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens
Aditya K. Padhi, Timir Tripathi
Briefings in Functional Genomics (2022) Vol. 22, Iss. 2, pp. 195-203
Closed Access | Times Cited: 9
IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 Intervention
Agata Blasiak, Anh T. L. Truong, Peter Wang, et al.
ACS Nano (2022) Vol. 16, Iss. 9, pp. 15141-15154
Closed Access | Times Cited: 9

Scroll to top